SAN ANTONIO, Texas — Powerhouse Therapeutics Inc today announced that Chief Executive Officer Vincent Pham will present new preclinical results for the company’s lead candidate, PH102, at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL (April 25-30).
Our poster, “Supercharging anti-tumor immunity in hepatocellular carcinoma with PH102: A CAR T-cell-based platform,” will be featured in the session “CAR Therapies: Emerging Approaches and Combinations” on Tuesday, April 29, 2025, from 2:00 p.m. to 5:00 p.m. The poster will be displayed in Poster Section 38, Board 20 (Poster #6112). Attendees can locate the exact position using the Poster Hall Map.
PH102 is an autologous CAR T-cell therapy that combines direct tumor lysis with immune activation and micro-environment modulation. In vivo models have demonstrated complete, durable tumor regression without dose-limiting toxicity. “These data strengthen our belief that PH102 can reset the liver tumor immune landscape and deliver meaningful clinical benefit,” said Mr. Pham. “AACR provides an ideal forum to engage collaborators and investors as we prepare for IND submission.”
About Powerhouse therapeutics
Powerhouse Therapeutics Inc is a biotechnology company developing cell-based therapies that tackle treatment resistance in solid tumors and fibrotic diseases. Built on our proprietary Immune Triad Therapy with Armed CAR T-cell Supercharger (IT-ACTS) platform, we engineer multimodal living drugs that deliver targeted payloads, remodel the tumor microenvironment, and restore tissue homeostasis. Our lead candidate, PH102, is an autologous IT-ACTS therapy poised for clinical entry, with off-the-shelf and anti-fibrotic programs advancing in parallel. Founded by leading academic scientists, we combine academic rigor with translational speed to deliver paradigm-shifting therapies for all patients.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including those regarding our future results of operations and financial position, business strategy, product candidates, and planned clinical trials, are forward-looking statements. You can identify these statements by words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “potential,” “continue,” or similar expressions, as well as discussions of future events or trends.
Forward-looking statements are subject to many risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, delays or failures in product development, clinical-trial outcomes that differ from preclinical data, adverse decisions by regulatory authorities, challenges in manufacturing or supply chains, our ability to secure and protect intellectual-property rights, competition in the marketplace, changes in healthcare regulations, and our need for additional financing. More information about these and other risks is included in our filings with the U.S. Securities and Exchange Commission.
We caution readers not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Powerhouse Therapeutics Inc undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or circumstances, except as required by law.
